Simultaneous quantification of losartan potassium and its active metabolite, EXP3174, in rabbit plasma by validated HPLC-PDA

Biomed Chromatogr. 2023 Aug;37(8):e5645. doi: 10.1002/bmc.5645. Epub 2023 Apr 22.

Abstract

Herein, we report a novel, accurate and cost-effective validated analytical method for the quantification of losartan potassium and its active metabolite, EXP 3174, in rabbit plasma by reversed-phase high-performance liquid chromatography. Valsartan was used as an internal standard. The method was validated as per International Conference on Harmonization guidelines. The analytes were extracted in rabbit plasma using liquid-liquid extraction technique and analyzed at 247 nm after separation through a reverse-phase C18 column. The isocratic mobile phase used is a mixture of acetonitrile, water and glacial acetic acid in the ratio of 60:40:1 v/v/v maintained at pH 3.4. All calibration curves showed a good linear relationship (r > 0.995) within the test range. Precision was evaluated by intra- and interday tests with RSDs <1.91% and accuracy showed validated recoveries of 86.20-101.11%. Based on our results, the developed method features good quantification parameters and can serve as an effective quality control method for the standardization of drugs.

Keywords: EXP 3174; HPLC; ICH; losartan potassium; method validation; rabbit plasma.

MeSH terms

  • Animals
  • Chromatography, High Pressure Liquid / methods
  • Losartan* / analysis
  • Quality Control
  • Rabbits
  • Reproducibility of Results
  • Valsartan

Substances

  • losartan carboxylic acid
  • Losartan
  • Valsartan